top of page

Ectica Technologies and SCREEN Holdings Co. Ltd are exhibiting at the AACR 2022 Annual Meeting

Updated: Jun 19, 2023

Ectica Technologies AG and SCREEN Holdings Co Ltd. are jointly exhibiting at the American Association for Cancer Research (AACR) 2022 taking place from April 8 to April 13 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

The AACR Annual Meeting 2022 - New Orleans

"The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. The AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world."

Tomographic imaging of organotypic cultures developed in the 3DProSeed hydrogel plate

Ectica Technologies and SCREEN will present their joint work related to label-free 3D tomographic imaging of organotypic cultures developed in the 3DProSeed hydrogel plate. The use of advanced ex vivo human organotypic cultures is rapidly growing in the field of oncology research and diagnostics, with a focus on patient-derived organoids and tumor tissue specimens cultured in artificial systems capable of replicating tumor development mechanisms. These mechanisms include metastasis, angiogenesis and formation of dysplasia. Our objective is to enhance the label-free imaging and analytical capabilities of these complex tissue samples to enable screening and diagnostics applications.

About SCREEN Holdings Co. Ltd technology

SCREEN Holdings Co Ltd has developed a unique infrared laser-based optical coherence tomography (technology equipped with an 890 nm center wavelength) light from a super luminescent diode and an objective (NA=0.3 high magnification lens), thereby, enabling non invasive, label-free, three dimensional 3D) imaging of tumoroids, epithelial cystic organoids, sprouting endothelial neo vasculature and metastatic single cells. We present culture and imaging protocols with the resulting 3D tomographic reconstructions of endothelial sprouting vessels, cystic epithelial organoids of the colon and 3D invasion assays of highly metastatic glioma cells.

About Ectica Technologies and 3DProSeed hydrogel plate

The 3DProSeed hydrogel plate developed by Ectica Technologies offers the highest workflow integration in screening processes. No hydrogel assembly step is necessary: the hydrogels are pre-casted in the plate and delivered hydrated and ready for cell seeding. Thanks to the patented hydrogel surface, no cell encapsulation procedures are required. Additionally, the hydrogels, made of poly(ethylene glycol)-based bioconjugates, are fully synthetic and animal free and offer the highest control over the culture conditions, as well as the possibility to upgrade to GMP for cell therapy applications. Finally, various cell populations can be sequentially seeded at different time points to generate complex co-cultures. In this way, stromal environments can be created under controlled conditions, to which cancer cells can be subsequently added.

Ectica Technologies is attending the AACR Annual Meeting 2022 in New Orleans


bottom of page